DDInter1033 DDInter899
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Leflunomide {u} (Compound) treats {v} (Disease) systemic scleroderma
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
Leflunomide {u} (Compound) downregulates {v} (Gene) MRPS16
Leflunomide {u} (Compound) causes {v} (Side Effect) Skin nodule
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Losartan
Leflunomide (Compound) resembles Niflumic Acid (Compound)
Leflunomide (Compound) treats systemic scleroderma (Disease)
Leflunomide (Compound) binds PTK2B (Gene)
Leflunomide (Compound) upregulates WIF1 (Gene)
Leflunomide (Compound) downregulates MRPS16 (Gene)
Leflunomide (Compound) causes Skin nodule (Side Effect)
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Losartan